Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis
Ping Yang, Hengheng Zhang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Jiuda Zhao, GuoShuang Shen, Yi Zhao · 2024
Read Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis by Ping Yang, Hengheng Zhang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Jiuda Zhao, GuoShuang Shen, Yi Zhao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11656431.txt.
Description
Ping Yang and nine colleagues pooled clinical trial data on liver toxicity from antibody-drug conjugates used in breast cancer. These targeted drugs deliver chemotherapy straight to cancer cells, but the liver still takes damage. The systematic review searched three databases through March twenty twenty-three. Liver enzyme elevations were the main measure. Incidence was combined across trials with meta-analysis, and drugs were compared against each other.
Overall rates of liver injury were high. Sacituzumab govitecan produced the highest rate of one enzyme's elevation, about twenty-five percent. Trastuzumab deruxtecan led for a second enzyme, at about thirty-two percent. Grades of severity were separated in the analysis. The twenty twenty-four ranking helps oncologists anticipate which conjugate needs the closest liver monitoring in breast cancer patients.
Catalog record
| CREATOR | Ping Yang, Hengheng Zhang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Jiuda Zhao, GuoShuang Shen, Yi Zhao |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |